Hypoglycemic agents and potential anti-inflammatory activity

Vishal Kothari,1 John A Galdo,2 Suresh T Mathews3 1Department of Nutrition and Dietetics, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, 2Department of Pharmacy Practice, 3Department of Nutrition and Dietetics, Samford University, Birmingham, AL, USA Abstract:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kothari V, Galdo JA, Mathews ST
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Diabetes Inflammation Insulin Metformin Thiazolidinedione Gliptin Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5cb3ad19b5c541d48bd816a3951616f2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5cb3ad19b5c541d48bd816a3951616f2
record_format	dspace
spelling	oai:doaj.org-article:5cb3ad19b5c541d48bd816a3951616f22021-12-02T01:06:23ZHypoglycemic agents and potential anti-inflammatory activity1178-7031https://doaj.org/article/5cb3ad19b5c541d48bd816a3951616f22016-04-01T00:00:00Zhttps://www.dovepress.com/hypoglycemic-agents-and-potential-anti-inflammatory-activity-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Vishal Kothari,1 John A Galdo,2 Suresh T Mathews3 1Department of Nutrition and Dietetics, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, 2Department of Pharmacy Practice, 3Department of Nutrition and Dietetics, Samford University, Birmingham, AL, USA Abstract: Current literature shows an association of diabetes and secondary complications with chronic inflammation. Evidence of these immunological changes include altered levels of cytokines and chemokines, changes in the numbers and activation states of various leukocyte populations, apoptosis, and fibrosis during diabetes. Therefore, treatment of diabetes and its complications may include pharmacological strategies to reduce inflammation. Apart from anti-inflammatory drugs, various hypoglycemic agents have also been found to reduce inflammation that could contribute to improved outcomes. Extensive studies have been carried out with thiazolidinediones (peroxisome proliferator-activated receptor- agonist), dipeptidyl peptidase-4 inhibitors, and metformin (AMP-activated protein kinase activator) with each of these classes of compounds showing moderate-to-strong anti-inflammatory action. Sulfonylureas and alpha glucosidase inhibitors appeared to exert modest effects, while the injectable agents, insulin and glucagon-like peptide-1 receptor agonists, may improve secondary complications due to their anti-inflammatory potential. Currently, there is a lack of clinical data on anti-inflammatory effects of sodium–glucose cotransporter type 2 inhibitors. Nevertheless, for all these glucose-lowering agents, it is essential to distinguish between anti-inflammatory effects resulting from better glucose control and effects related to intrinsic anti-inflammatory actions of the pharmacological class of compounds. Keywords: diabetes, inflammation, insulin, metformin, thiazolidinedione, gliptinKothari VGaldo JAMathews STDove Medical PressarticleDiabetesInflammationInsulinMetforminThiazolidinedioneGliptinPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2016, Iss Issue 1, Pp 27-38 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetes Inflammation Insulin Metformin Thiazolidinedione Gliptin Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Diabetes Inflammation Insulin Metformin Thiazolidinedione Gliptin Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Kothari V Galdo JA Mathews ST Hypoglycemic agents and potential anti-inflammatory activity
description	Vishal Kothari,1 John A Galdo,2 Suresh T Mathews3 1Department of Nutrition and Dietetics, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, 2Department of Pharmacy Practice, 3Department of Nutrition and Dietetics, Samford University, Birmingham, AL, USA Abstract: Current literature shows an association of diabetes and secondary complications with chronic inflammation. Evidence of these immunological changes include altered levels of cytokines and chemokines, changes in the numbers and activation states of various leukocyte populations, apoptosis, and fibrosis during diabetes. Therefore, treatment of diabetes and its complications may include pharmacological strategies to reduce inflammation. Apart from anti-inflammatory drugs, various hypoglycemic agents have also been found to reduce inflammation that could contribute to improved outcomes. Extensive studies have been carried out with thiazolidinediones (peroxisome proliferator-activated receptor- agonist), dipeptidyl peptidase-4 inhibitors, and metformin (AMP-activated protein kinase activator) with each of these classes of compounds showing moderate-to-strong anti-inflammatory action. Sulfonylureas and alpha glucosidase inhibitors appeared to exert modest effects, while the injectable agents, insulin and glucagon-like peptide-1 receptor agonists, may improve secondary complications due to their anti-inflammatory potential. Currently, there is a lack of clinical data on anti-inflammatory effects of sodium–glucose cotransporter type 2 inhibitors. Nevertheless, for all these glucose-lowering agents, it is essential to distinguish between anti-inflammatory effects resulting from better glucose control and effects related to intrinsic anti-inflammatory actions of the pharmacological class of compounds. Keywords: diabetes, inflammation, insulin, metformin, thiazolidinedione, gliptin
format	article
author	Kothari V Galdo JA Mathews ST
author_facet	Kothari V Galdo JA Mathews ST
author_sort	Kothari V
title	Hypoglycemic agents and potential anti-inflammatory activity
title_short	Hypoglycemic agents and potential anti-inflammatory activity
title_full	Hypoglycemic agents and potential anti-inflammatory activity
title_fullStr	Hypoglycemic agents and potential anti-inflammatory activity
title_full_unstemmed	Hypoglycemic agents and potential anti-inflammatory activity
title_sort	hypoglycemic agents and potential anti-inflammatory activity
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/5cb3ad19b5c541d48bd816a3951616f2
work_keys_str_mv	AT kothariv hypoglycemicagentsandpotentialantiinflammatoryactivity AT galdoja hypoglycemicagentsandpotentialantiinflammatoryactivity AT mathewsst hypoglycemicagentsandpotentialantiinflammatoryactivity
_version_	1718403318424797184

Hypoglycemic agents and potential anti-inflammatory activity

Ejemplares similares